Wendt Lab, based in West Lafayette, IN, is a research facility dedicated to investigating the molecular mechanisms involved in metastatic breast cancer and developing targeted pharmacological interventions. Their focus lies in understanding and overcoming the process of epithelial-mesenchymal transition (EMT), which is associated with tumor invasion, metastasis, acquisition of drug resistance, and the development of a stem-cell phenotype. Through genetic and pharmacologic manipulation, as well as the use of three-dimensional cell culture and in vivo mouse models, Wendt Lab aims to identify potential targets for therapeutic resistance and elucidate their role in EMT and drug resistance.
Recently relocated to the Holden Comprehensive Cancer Center at the University of Iowa, Wendt Lab conducts cutting-edge research and has made significant contributions to the field, as evidenced by their publications in prestigious scientific journals. Their work involves utilizing in vivo optical imaging to track and quantify cell behavior, location, and activation of specific signaling pathways, providing valuable insights into the complex processes underlying metastatic breast cancer. With a team of dedicated researchers and a focus on understanding the molecular basis of cancer progression, Wendt Lab is at the forefront of advancing knowledge and developing novel therapeutic strategies for combating metastatic breast cancer.
Generated from the website